Due the results of the BREAKWATER trial, the FDA recently gave accelerated approval for the use of encorafenib with cetuximab and mFOLFOX6 (5-FU, leucovorin, oxaliplatin) in patients with treatment naïve metastatic BRAFV600E CRC increasing the patient population who will be receiving BRAF and EGFR inhibitor therapy [3]. This evidence concerns the gene EGFR and colorectal carcinoma.